L-R Stephanie Hall, Uptake Founder and CEO; Jason McKenna, Prescient CEO
Prescient (Prescient Healthcare Group) has acquired Uptake (Uptake Strategies), a global healthcare consultancy.
This strategic move marks the beginning of an exciting new chapter for both companies, combining complementary expertise and shared values to deliver exceptional impact for pharmaceutical and biotech clients and the patients they serve worldwide.
Prescient is an international consulting partner to the biopharmaceutical industry, with offices in the US, UK, India, Spain and Germany.
Prescient operates across three core practices:
- Medical, led by Luke Solon
- Competitive Strategy, led by Ryan Caradonna
- Commercial Practice (newly combined), to be co-led by Prescient’s Simon Campling and Uptake’s Managing Director, Maxine Smith.
Stephanie Hall, CEO and Founder of Uptake, will assume the role of Global Practice Lead – Commercial and will join the Prescient Board, ensuring continuity of Uptake’s values, culture and dedication to delivering exceptional performance for clients throughout the integration.
Jason McKenna, CEO of Prescient, commented: “We are delighted to welcome Uptake to Prescient. Uptake’s reputation for excellence, innovation and cultural integrity aligns perfectly with our own ambitions.
“This partnership strengthens our ability to deliver integrated commercial, medical and strategic solutions for clients globally, ultimately benefiting patients through better-informed decisions.”
Stephanie Hall, CEO of Uptake, added: “When seeking a partner for our next chapter, Prescient stood out for its cultural alignment and shared commitment to purpose.
“This next phase of Uptake’s growth will unlock new opportunities for our people and clients, while preserving the values that have defined us for 20 years. I am excited to join the Prescient Board and lead the combined Commercial Practice as we scale together.”
Alan Payne, Partner and Deputy Head of Bridgepoint Development Capital, said: “This acquisition is a strong strategic fit for Prescient, adding highly complementary commercial and launch expertise. Since partnering with Bridgepoint in 2021, Prescient has proven its ability to integrate high-quality businesses, and this transaction reflects a disciplined approach to scaling its platform while continuing to deliver strong outcomes for clients and patients.”
This joining of forces reflects both Uptake’s and Prescient’s strategic growth ambitions, which are focused on combined global reach and innovation. Prescient’s proven track record in successful integrations, including its acquisition of Strategic North in 2022, ensures a smooth transition with minimal disruption to clients and teams.
Both companies share a strong values-led culture, with Prescient’s B-Corp certification reinforcing its commitment to purpose and sustainability. Integration planning is already underway, guided by principles designed to maximise the benefits of clear synergies, increased capacity and combined strengths to deliver further positive impact.
For now, Uptake will continue to operate under its existing brand, with an initial reference to being ‘part of Prescient’ across communications.
Further brand evolution will follow as integration progresses.
Together, Prescient and Uptake will combine global scale and deep expertise, to deliver transformative solutions for pharma and biotech clients, and better outcomes for patients worldwide.
Prescient is a science- and insight-led development and commercialisation partner that works with pharma and biotech companies. Uptake is a global healthcare consultancy. The transaction is supported by Prescient’s existing investment partner Bridgepoint, which partnered with the company in 2021.